

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Gosselin <i>et al.</i>	Confirmation No.:	9603
Application No.:	09/371,747	Art Unit:	1623
Filed:	August 10, 1999		
Patent No.:	6,395,716	Examiner:	Crane, Lawrence E
Issued:	May 28, 2002		
For:	β -L-2'-DEOXYNUCLEOSIDES FOR TREATMENT OF HEPATITIS B	Attorney Docket No.:	11874-005-999

SUBMISSION UNDER 37 C.F.R. § 1.765

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.765 and M.P.E.P. § 2762, Applicants hereby direct the Patent Office's attention to the document listed below in connection with the determination of entitlement to the extension of the term of U.S. Pat. No. 6,395,716, filed December 21, 2006. Applicants respectfully request that the Patent Office make the following document of record:

(1) US Securities and Exchange Commission Form 8-K, for Idenix Pharmaceuticals, Inc., dated July 30, 2008, with Exhibit Index 10.1 – Settlement Agreement, effective June 1, 2008, between The Board of Trustees of the University of Alabama on behalf of the University of Alabama at Birmingham, The University of Alabama Research Foundation, Emory University, Idenix Pharmaceuticals, Inc., Jean-Pierre Sommadossi, the Université Montpellier II, and the Centre National de la Recherche Scientifique et Technological Public Establishment.


CONCLUSION

Applicants respectfully request that the document submitted herein be made of record.

No fee is believed to be due in connection with this submission. However, if any fee is required, please change the amount of any such fee to Jones Day Deposit Account No. 50-3013 (order no. 417451-999005).

Respectfully submitted,

Date: January 8, 2009



Rahul Pathak 42,983
(Reg. No.)
For: Anthony M. Insogna, Esq. (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939